MedTrace Logo

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

NCT01677884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-06-09

No results posted yet for this study

Summary

The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Bevacizumab

Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1

DRUG

Capecitabine

Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4

DRUG

Irinotecan

Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Michel Ducreux, MD-PhD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01677884 on ClinicalTrials.gov